Last updated 9 days ago
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
1200 patients around the world
Available in Puerto Rico, Chile, Costa Rica, Argentina, United States
Merck Sharp & Dohme LLC
10Research sites
1200Patients around the world
This study is for people with
Breast Cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Sociedad de Beneficencia Hospital Italiano - Córdoba
Recruiting
Sociedad de Beneficencia Hospital Italiano - Córdoba
Recruiting
Instituto Médico de la Fundación Estudios Clínicos - Rosario
Recruiting
Instituto Médico de la Fundación Estudios Clínicos - Rosario
Recruiting
Hospital Alemán
Recruiting
Hospital Alemán
Recruiting
Clínica RedSalud Vitacura
Recruiting
Clínica RedSalud Vitacura
Recruiting
Hospital Clínico Pontificia Universidad Católica de Chile - Santiago, Región Metropolitana
Recruiting
Hospital Clínico Pontificia Universidad Católica de Chile - Santiago, Región Metropolitana
Recruiting
Oncovida - Santiago
Recruiting
Oncovida - Santiago
Recruiting
Clínica CIMCA
Recruiting
Clínica CIMCA
Recruiting
ICIMED Instituto de Investigación en Ciencias Médicas
Recruiting
ICIMED Instituto de Investigación en Ciencias Médicas
Recruiting
Hospital Metropolitano - Sede Lindora
Recruiting
Hospital Metropolitano - Sede Lindora
Recruiting
Puerto Rico Medical Research Center
Recruiting
Puerto Rico Medical Research Center
Recruiting
StudyMK 2870-010
SponsorMerck Sharp & Dohme LLC
Conditions
Breast Cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06312176
